Eltanexor Effectively Reduces Viability of Glioblastoma and Glioblastoma Stem-Like Cells at Nano-Molar Concentrations and Sensitizes to Radiotherapy and Temozolomide
Current standard adjuvant therapy of glioblastoma multiforme (GBM) using temozolomide (TMZ) frequently fails due to therapy resistance. Thus, novel therapeutic approaches are highly demanded. We tested the therapeutic efficacy of the second-generation XPO1 inhibitor Eltanexor using assays for cell v...
Saved in:
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Philipps-Universität Marburg
2022
|
Subjects: | |
Online Access: | PDF Full Text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Internet
PDF Full TextCall Number: |
urn:nbn:de:hebis:04-es2023-00588 |
---|---|
Publication Date: |
2023-05-16 |
Source: |
Erstveröffentlichung: Otte, K.; Zhao, K.; Braun, M.; Neubauer, A.; Raifer, H.; Helmprobst, F.; Barrera, F.O.; Nimsky, C.; Bartsch, J.W.; Rusch, T. Eltanexor Effectively Reduces Viability of Glioblastoma and Glioblastoma Stem-like Cells at Nano-Molar Concentrations and Sensitizes to Radiotherapy and Temozolomide. Biomedicines 2022, 10, 2145. https://doi.org/10.3390/biomedicines10092145 |
Downloads: |
49 (2024), 44 (2023) |
License: |
https://creativecommons.org/licenses/by/4.0 |
Access URL: |
https://archiv.ub.uni-marburg.de/es/2023/0058 https://doi.org/10.3390/biomedicines10092145 |